Highnoon Partners with Bangladesh’s Beximco to Bring Advanced Respiratory, Diabetes, and Cardiac Treatments to Pakistan

Pakistani pharmaceutical firm Highnoon Laboratories Limited (PSX: HINOON) Tuesday announced that it has entered into a strategic partnership with Beximco Pharmaceuticals Limited, a leading Bangladesh based pharmaceutical company having state-of-the-art manufacturing facilities. In a notice to the Pakistan Stock Exchange (PSX), the firm also highlighted that Beximco is accredited by the regulatory authorities of USA, Australia, European Union, Canada, and Brazil. An MoU has been signed between the company and Beximco Pharmaceuticals Limited to collaborate for the distribution and marketing of specialized pharmaceutical products in Pakistan, with the focus on high- burden therapeutic areas including respiratory, diabetes, and cardiovascular diseases, the notice said. Through this partnership the company will bring newer therapies, dosage forms and delivery systems for the ease of use and better clinical results for patients and improving access to the advanced medications. This strategic alliance will make a significant contribution to the recent expansion of trade relations and economic cooperation between Pakistan and Bangladesh.